Key Insights

Highlights

Success Rate

75% trial completion

Treatment Research

4 treatments under study, led by Kw3357

Related Conditions

Often studied with 9 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 52/100

Termination Rate

14.3%

1 terminated out of 7 trials

Success Rate

75.0%

-11.6% vs benchmark

Late-Stage Pipeline

43%

3 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed with results

Key Signals

75% success

Data Visualizations

Phase Distribution

4Total
Not Applicable (1)
Phase 3 (3)

Trial Status

Not Yet Recruiting3
Completed3
Terminated1

Trial Success Rate

75.0%

Benchmark: 86.6%

Based on 3 completed trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT07897006Not ApplicableNot Yet Recruiting

Safflower (Carthamus Tinctorius L.) Granules for Sepsis-associated Coagulopathy

NCT07630415Not Yet RecruitingPrimary

EARLY DIAGNOSIS OF SEPTIC DIC

NCT07585942Not Yet Recruiting

Fluorescent Leukocytes as a Marker of Early Sepsis/Severity

NCT06860503Completed

Thrombelastography for Coagulopathy in Chinese Snakebites

NCT01384396Phase 3CompletedPrimary

A Clinical Study of KW-3357 in Patients With DIC

NCT01384409Phase 3TerminatedPrimary

A Phase 3 Clinical Study of KW-3357 in Patients With DIC

NCT01384903Phase 3CompletedPrimary

An Open-label Study of KW-3357

Showing all 7 trials

Research Network

Common Treatments

  • Kw33573
  • Highdose Safflower Granules1
  • Plasmaderived Antithrombin1
  • Mediumdose Safflower Granules1

Active Sponsors

  • Kyowa Kirin Co., Ltd.3
  • University Hospital, Strasbourg, France2
  • Shanghai Jiao Tong University School of Medicine1
  • Hansung University1

Top Investigators

  • Li Ma, MD, PhD1

    Emergency Department, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine

Related Conditions

  • Sepsis2
  • Septic Shock2
  • Pit Viper Bite1
  • Reanimation1
  • Coagulation Disorder1

Activity Timeline